Sarcopenia is a condition characterized by the loss of skeletal muscle mass, strength, and function that occurs as a natural part of the aging process. The global sarcopenia treatment market is expected to grow significantly in the coming years due to the increasing geriatric population and rising awareness about sarcopenia.
Market Overview:
Increasing out-of-pocket healthcare expenditure is the major factor expected to boost the demand for sarcopenia treatment supplement. According to the National Health Expenditure Accounts (NHEA), the U.S. health care spending grew 4.3 percent in 2016, reaching US$ 3.3 trillion or US$ 10,348 per person
How About Looking Through The Sample Of Sarcopenia Treatment Market Report? https://www.persistencemarketresearch.com/samples/15694
Treatment Types:
The sarcopenia treatment market can be segmented into pharmacological treatment, non-pharmacological treatment, and combination treatment. The pharmacological treatment segment held the largest market share in 2020 due to the availability of drugs such as anabolic steroids, growth hormone secretagogues, and myostatin inhibitors. Non-pharmacological treatment options include exercise, nutrition, and hormone replacement therapy. Combination therapy includes a combination of pharmacological and non-pharmacological treatments.
Regional Analysis:
North America held the largest share of the sarcopenia treatment market in 2020 due to the high prevalence of sarcopenia and the availability of advanced healthcare facilities in the region. Europe is expected to be the fastest-growing market for sarcopenia treatment during the forecast period due to the rising geriatric population and increasing awareness about sarcopenia in the region. The Asia Pacific region is also expected to grow significantly due to the increasing healthcare expenditure and rising awareness about sarcopenia.
Key Players:
The key players in the sarcopenia treatment market include Novartis AG, GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., Abbott Laboratories, Sanofi S.A., Nestle S.A., Amway Corporation, Danone S.A., and Herbalife International of America, Inc.
Conclusion:
The global sarcopenia treatment market is expected to grow significantly in the coming years due to the increasing geriatric population and rising awareness about sarcopenia. The pharmacological treatment segment held the largest market share in 2020, but non-pharmacological treatment options such as exercise and nutrition are gaining popularity. North America held the largest share of the market in 2020, but Europe is expected to be the fastest-growing market during the forecast period.